Compare Chevron Corp (CVX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Nuwellis Inc — how do they compare? Chevron Corp trades at $181.79 (market cap $361.99B), while Nuwellis Inc trades at $3.4 (market cap $1.17M). The key difference: Chevron Corp is far larger — about 309393.2× Nuwellis Inc's market cap, and Chevron Corp pays a 3.92% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| CVX | NUWE | |
|---|---|---|
Market Cap | $361.99B | $1.17M |
Volume | 9,807,834 | — |
Sector | Energy | Technology |
52-Week High | $211.14 | $558.26 |
52-Week Low | $146.72 | $2.80 |
Enterprise Value | $402.09B | -$636.97K |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $181.77, up 3.04% today, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten estimates, though revenue and net income have declined year-over-year. The company maintains solid cash flow from operations and recently announced a $13.8 billion investment in Argentina's Vaca Muerta shale play, signaling growth commitment. High oil prices and geopolitical tensions are key near-term catalysts.
Outlook remains positive given Wall Street's $207.56 price target and 62% buy ratings, but risks include declining profit margins, volatile oil prices, and execution challenges on new projects. The stock offers value through dividends and strategic expansion, yet investors face headwinds from macroeconomic uncertainty and competitive pressures.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
